Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for Patient-Centred Therapy

Okwuosa, Tochukwu Chijioke; Pereira, Beatriz C.; Arafat, Basel; Cieszynska, Milena; Isreb, Abdullah; Alhnan, Mohamed Albed

doi:10.1007/s11095-016-2073-3

Cited by 226 publications

(160 citation statements)

References 38 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…Fused deposition modelling (FDM) 3D printing has therefore been proposed as an alternative method for 3D printing of tablets [16,17] and medical devices [18]. The method allows the fabrication of immediate [19][20][21], delayed [22,23], extended release tablets [24][25][26][27][28] as well as for dual drug delivery systems [29][30][31]. The technology offers several advantages such as the lower cost, absence of finishing step, small place requirement and obviation for material recycling [13,32].…”

Section: Introductionmentioning

confidence: 99%

‘Temporary Plasticiser’: A novel solution to fabricate 3D printed patient-centred cardiovascular ‘Polypill’ architectures

Pereira

Isreb

Forbes

et al. 2019

European Journal of Pharmaceutics and Biopharmaceutics

Self Cite

148

View full text Add to dashboard Cite

Hypertension and dyslipidaemia are modifiable risk factors associated with cardiovascular diseases (CVDs) and often require a complex therapeutic regimen. The administration of several medicines is commonly associated with poor levels of adherence among patients, to which World Health Organisation (WHO) proposed a fixed-dose combination unit (polypill) as a strategy to improve adherence. In this work, we demonstrate the fabrication of patient-specific polypills for the treatment of CVDs by fused deposition modelling (FDM) 3D printing and introduce a novel solution to meet critical quality attributes. The construction of poly(vinyl alcohol) (PVA)-based polypills containing four model drugs (lisinopril dihydrate, indapamide, rosuvastatin calcium and amlodipine besylate) was revealed for the first time. The impact of tablet architecture was explored using multi-layered and unimatrix structures. The novel approach of using distilled water as a 'temporary co-plasticiser' is reported and was found to significantly lower the extruding (90°C) and 3D printing (150°C) temperatures from 170°C and 210°C respectively, with consequent reduction in thermal stress to the chemicals. XRD indicated that lisinopril dihydrate and amlodipine besylate maintained their crystalline form while indapamide and rosuvastatin calcium were essentially amorphous in the PVA tablets. From the multilayer polypills, the release profile of each drug was dependent on its position in the multilayer.In addition to the multilayer architecture offering a higher flexibility in dose titration and a more adaptive solution to meet the expectations of patient-centred therapy, we identify that it also allows orchestrating the release of drugs of different physicochemical characteristics. Adopting such an approach opens up a pathway towards low-cost multidrug delivery systems such as tablets, stents or implants for wider range of globally approved actives.

show abstract

Section: Introductionmentioning

confidence: 99%

‘Temporary Plasticiser’: A novel solution to fabricate 3D printed patient-centred cardiovascular ‘Polypill’ architectures

Pereira

Isreb

Forbes

et al. 2019

European Journal of Pharmaceutics and Biopharmaceutics

Self Cite

148

View full text Add to dashboard Cite

show abstract

“…These results confirm that the fused deposition modeling 3DP makes possible the production of delayed-release printlets, without the need of enteric coating. Okwuosa et al [32] managed to fabricate shell-core delayed-release tablets of theophylline, budesonide, and diclofenac sodium with dual fused deposition modeling 3D printing and hot-melt extrusion. For the core structure, filaments consisting of the polymer (PVP), plasticizer (triethyl citrate), filler (talc) or tribasic phosphate sodium, and the active ingredient were created with hot-melt extrusion.…”

Section: An Overview Of the 3dp Technique Applications In Modified Pementioning

confidence: 99%

3D-Printed Modified-Release Tablets: A Review of the Recent Advances

Siamidi¹,

Tsintavi²,

Rekkas³

et al. 2020

Molecular Pharmacology

View full text Add to dashboard Cite

The broad spectrum of applications of three-dimensional printing (3D printing, 3DP) has attracted the attention of researchers working in diverse fields. In pharmaceutics, the main idea behind 3D printing products is to design and develop delivery systems that are suited to an individual's needs. In this way, the size, appearance, shape, and rate of delivery of a wide array of medicines could be easily adjusted. The aim of this chapter is to provide a compilation of the 3D printing techniques, used for the fabrication of oral drug delivery systems, and review the relevant scientific developments in particular those with modified-release characteristics.

show abstract

“…Nevertheless, one key limitation of printing drugs via FDM remains: as the filament composition is fixed, the freedom to tailor drug dose or drug combinations is significantly limited. Recent work attempted to address this by producing delayedrelease and shell-core tablets using a dual FDM head set-up [11]. However, as FDM creates layers in a vector fashion, that is, one head at a time, adding more heads can significantly increase mechanical complexity, as well as the processing time.…”

Section: Fused Deposition Modeling 3dp Of Drugsmentioning

confidence: 99%